Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

PureTech (PRTC)

Price 139.60p on 20-01-2025 at 17:30:00
Change -2.40p -1.69%
Buy 140.40p
Sell 139.40p
Buy / Sell PRTC Shares
Last Trade: Buy 61,610.00 at 139.60p
Day's Volume: 282,093
Last Close: 139.60p
Open: 140.20p
ISIN: GB00BY2Z0H74
Day's Range 139.40p - 141.80p
52wk Range: 136.00p - 238.50p
Market Capitalisation: £334m
VWAP: 140.56454p
Shares in Issue: 239m

Recent Trades History PureTech (PRTC)

Buy/Sell Volume Trade Prc Trade Type Trade Time
Buy* 61,610 139.60p Suspected BUY Trade
16:35:02 - 20-Jan-25
Sell* 678 139.60p Automatic Execution
16:29:44 - 20-Jan-25
Sell* 161 139.60p Automatic Execution
16:29:44 - 20-Jan-25
Sell* 173 139.60p Automatic Execution
16:29:44 - 20-Jan-25
Sell* 183 139.60p Automatic Execution
16:29:44 - 20-Jan-25
Sell* 476 139.60p Automatic Execution
16:28:50 - 20-Jan-25
Buy* 17 140.00p Automatic Execution
16:28:50 - 20-Jan-25
Buy* 788 139.676p Ordinary
16:25:46 - 20-Jan-25
Buy* 539 139.60p Automatic Execution
16:21:44 - 20-Jan-25
Buy* 500 139.60p Automatic Execution
16:21:44 - 20-Jan-25

Share Price History for PureTech

Time period:
to
Date Open High Low Close Volume

Share News for PureTech

PureTech receives FDA fast track designation for leukemia treatment

9th Jan 2025 12:26

(Alliance News) - PureTech Health PLC on Thursday said that the US Food & Drug Administration has granted fast track designation to its antibody LYT-200 for the treatment of acute myeloid leukemia. Read More

IN BRIEF: PureTech Health says LYT-100 slows lung function decline

16th Dec 2024 14:35

PureTech Health PLC - Boston, Massachusetts-based biotechnology company - Notes that deupirfenidone, also known as LYT-100, slows lung function decline in people with idiopathic pulmonary fibrosis as measured by forced vital capacity in a phase 2b trial. Toby Maher, professor of medicine & director of interstitial lung disease at Keck School of Medicine at the University of Southern California in Los Angeles, and lead investigator in the Elevate IPF trial, says: "Deupirfenidone has the potential to offer patients a highly effective and tolerable treatment option. These are extremely exciting results from a phase 2b trial, and I am very enthusiastic about the continued development of deupirfenidone." Read More

LONDON BRIEFING: Vodafone-Three deal green lit; Shell and Equinor team

5th Dec 2024 07:59

(Alliance News) - London's FTSE 100 is called to open slightly lower on Thursday, despite US stocks spiking to record highs overnight. Read More

TOP NEWS: Retail pair and under-pressure Vistry booted out of FTSE 100

4th Dec 2024 18:15

(Alliance News) - Frasers Group PLC has been relegated from the FTSE 100 index in its latest quarterly shuffle alongside two constituent peers, housebuilder Vistry Group PLC and variety goods retailer B&M European Value Retail SA. Read More

PureTech Health investigates IPF disease burden amid treatment testing

9th Oct 2024 10:03

(Alliance News) - PureTech Health PLC on Wednesday said a new patient survey for people with idiopathic pulmonary fibrosis has provided new insights into disease burden and patient experience. Read More

FTSE 100 Latest
Value8,520.54
Change15.32

Login to your account

Forgot Password?

Not Registered